The recent 2025 scientific statement from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the ESC Working Group on Cardiovascular Pharmacotherapy (DOI: 10.1002/ejhf.70090) spotlights this issue, framing non-adherence through six interconnected dimensions: patient-related, therapy-related, condition-related, system-related, socioeconomic-related, and environmental-related. This model builds on the World Health Organization’s (WHO) classic five dimensions by adding an environmental lens to capture geographical and logistical challenges.
But how does a provider move from detection—often via tools like the 8-item Morisky Medication Adherence Scale (MMAS-8)—to actionable improvement? Enter strategies inspired by the Morisky Adherence Action Plan (MAAP), a proven framework from moriskyscale.com designed to assess adherence, predict risks, and craft personalized interventions. MAAP, which leverages the Morisky scales (e.g., MMAS-8) to categorize adherence as low, medium, or high while pinpointing intentional or unintentional barriers, aligns seamlessly with the ESC’s multidimensional approach. By adapting MAAP’s core steps—assessment, risk prediction using WHO-like dimensions, action planning with targeted education and support, and ongoing measurement—providers can systematically uncover and address each of the six dimensions. This not only boosts GDMT persistence (e.g., from a dismal 5–67% in real-world data) but also enhances outcomes like reduced mortality and readmissions.
Let’s dive into a step-by-step guide for providers: After flagging non-adherence with MMAS-8 (a quick, validated self-report tool scoring 0–8, where <6 signals issues), use targeted questioning, history-taking, and multidisciplinary input to explore the dimensions. Then, deploy MAAP-inspired tactics: personalize interventions, educate on barriers, monitor progress, and adjust plans dynamically. Here’s how it plays out for each dimension in HF care.
Patient-Related Dimension: Beliefs, Behaviors, and Beyond
This dimension encompasses personal factors like forgetfulness, low self-efficacy, depression, cognitive impairment, or misconceptions about medications (e.g., “I feel fine, so I don’t need my beta-blocker”). Providers can uncover it by following up MMAS-8 results with open-ended questions: “What makes it hard to remember your pills?” or “Do you worry about long-term effects?”
MAAP-inspired strategies: Start with risk prediction—use MMAS-8 domains to classify intentional (e.g., stopping when feeling better) vs. unintentional (e.g., forgetting) non-adherence. Develop a personalized action plan with education sessions (≥3 face-to-face or virtual) to reframe beliefs, build self-efficacy through goal-setting, and integrate mental health support (e.g., screening for depression, which predicts poorer adherence). Involve caregivers for cognitive challenges. Monitor via follow-up MMAS-8 scores, aiming for incremental improvements that could cut death risks by 2–11%.
Therapy-Related Dimension: Regimen Complexity and Side Effects
Here, barriers stem from the treatment itself—polypharmacy (HF patients often juggle 5+ meds), frequent dosing, or side effects like fatigue from beta-blockers or hypotension from ARNi. Uncover by asking: “Do side effects bother you?” or reviewing refill patterns for inconsistencies.
Drawing from MAAP: After assessment, predict risks tied to regimen burden and craft interventions like simplifying to once-daily options or de-prescribing non-essentials. A standout tactic: Advocate fixed-dose polypills (combining GDMT elements), which MAAP endorses for reducing pill counts by ~31% and enhancing compliance. Provide targeted education on managing side effects, and collaborate with pharmacists for routine reviews. Measure success through objective metrics like Proportion of Days Covered (PDC ≥80%), tracking reduced adverse events.
Condition-Related Dimension: Disease Burden and Comorbidities
HF’s symptom severity, progression, or comorbidities (e.g., CKD limiting SGLT2i dosing, COPD complicating breathing meds) can erode adherence. Probe with: “How do your symptoms affect your ability to take meds?” or assess via tools like the European Heart Failure Self-care Behaviour Scale (EHFScB-9).
MAAP alignment: Use the framework’s risk prediction to link condition factors to non-adherence domains. Action plans might include multidisciplinary tailoring—e.g., remote monitoring (as in TIM-HF2 trials, cutting events by 20–30%) to adjust therapies amid flares. Educate on connecting adherence to symptom relief for motivation, and involve specialists for comorbidities. Ongoing measurement ensures adaptations, fostering better self-care in chronic HF.
System-Related Dimension: Care Delivery Gaps
Fragmented follow-ups, poor provider communication, or access hurdles fall here. Uncover through history: “How often do you see your doctor?” or by noting missed appointments in records.
MAAP strategies: Post-assessment, predict system risks and build action plans with enhanced support—embed routine adherence checks (e.g., MMAS-8 in workflows) and deploy multidisciplinary teams (nurses, pharmacists) for frequent contacts and reconciliation. Digital tools like apps or text reminders mirror MAAP’s monitoring emphasis, improving engagement. Measure via utilization data, targeting 15–20% adherence gains.
Socioeconomic-Related Dimension: Financial and Educational Barriers
Costs (e.g., co-pays dropping adherence per $7.80 increase), low health literacy, or education gaps amplify risks. Ask: “Is cost a concern?” or screen literacy with simple tools.
Inspired by MAAP: Risk prediction highlights these as WHO-style social/economic factors. Interventions include cost-relief programs, affordable alternatives (e.g., ACEi over ARNi), and culturally sensitive education with visuals. MAAP’s personalized plans ensure monitoring for equity, reducing disparities in vulnerable groups like the elderly or low-income patients.
Environmental-Related Dimension: Logistical and Geographical Challenges
The ESC’s innovative addition covers rural-urban disparities, social isolation, language barriers, or cultural beliefs. Uncover: “Does distance to your pharmacy affect refills?” or assess support networks.
MAAP adaptation: While MAAP uses five WHO dimensions, extend its framework by incorporating environmental risks into action plans—e.g., telehealth for remote access, community programs, or family involvement to combat isolation. Provide tailored education addressing cultural factors, and monitor with digital ecosystems to bridge gaps, aligning with MAAP’s goal of holistic, measurable improvements.
From Insight to Impact: Implementing MAAP in Practice
By weaving MAAP’s structured approach—assess with MMAS-8, predict multidimensional risks, plan personalized fixes, and measure outcomes—providers can transform non-adherence from a hidden threat to a conquered challenge. In HF, this means fewer crises, better quality of life, and cost savings that outweigh interventions. Tools like MMAS-8, available for licensing at moriskyscale.com, make it accessible for clinics, trials, or chronic care (e.g., Medicare CPT 99490).
Ready to elevate adherence? Visit moriskyscale.com to explore MAAP and MMAS resources today. Share your experiences in the comments—what’s one dimension you’ve tackled successfully?
Note: Always consult the full ESC statement

The 2025 ESC scientific statement on adherence to guideline-directed medical treatments in heart failure (DOI: 10.1002/ejhf.70090) primary focus on validated tools appears in Box 1 (“Practical tools for measuring adherence”), which lists a small set of practical, evidence-based options suitable for clinical practice and research in HF populations. These are intended to help identify non-adherence overall and uncover potential barriers across dimensions, rather than being dimension-specific:

1. ​Morisky Medication Adherence Scale (MMAS-8)
2. European Heart Failure Self-care Behaviour Scale (EHFScB-9)
3. Pharmacy refill data

​
ESC recommends addressing each of the six dimensions:
​• Patient-related factors (e.g., beliefs, forgetfulness, low self-efficacy, depression/anxiety, cognitive impairment, age/sex differences):
Empower patients through structured education (≥3 face-to-face or home-based sessions, extended to caregivers) to build understanding of HF, medication rationale, and self-care skills. Promote shared decision-making and self-efficacy to foster ownership. Address mental health via integrated psychological support, as depression strongly predicts poorer adherence. Use simple tools like digital reminders/apps for forgetfulness and involve caregivers for elderly or cognitively impaired patients.
• Therapy-related factors (e.g., polypharmacy, complex regimens, side effects like hypotension/fatigue, frequent dosing):
Simplify treatment wherever possible—prioritize once-daily dosing, long half-life agents, or de-prescribing unnecessary drugs. Strongly advocate fixed-dose polypills (single-pill GDMT combinations) for stable patients after achieving target doses, which reduce pill burden, minimize confusion, and improve adherence by ~31% while lowering mortality risk by ~10% in cardiovascular settings. Routine medication reviews by pharmacists help manage side effects and up-titration tolerability.
• Condition-related factors (e.g., symptom severity, comorbidities like CKD/COPD/cognitive disorders, disease progression):
Tailor GDMT adjustments via multidisciplinary teams and remote monitoring to enhance tolerability amid comorbidities. Educate patients on linking symptom relief/improvement to therapy adherence for motivation. Involve specialists (e.g., geriatricians) and use real-time data from digital tools to adapt therapies proactively, reducing adverse reactions from polypharmacy.
• System-related factors (e.g., limited follow-up, fragmented care, provider overestimation of adherence, access barriers):
Embed routine adherence assessment (e.g., proportion of days covered <80% threshold, self-report tools like MMAS-8) into clinical workflows. Deploy multidisciplinary teams (nurses, pharmacists, specialists) for frequent contacts, education, up-titration support, and medication reconciliation—shown to boost adherence by 15–20%. Integrate digital ecosystems (text reminders, apps, remote monitoring like in the TIM-HF2 trial) for ongoing support and event reduction (up to 20–30% fewer HF events).
• Socioeconomic-related factors (e.g., financial constraints, low health literacy/education, insurance gaps):
Mitigate cost barriers through reduced co-payments, free medications where feasible, patient assistance programs, or affordable alternatives (e.g., ACEi/ARB when ARNi is unaffordable). Use simplified, culturally sensitive communication with visual aids for low-literacy groups. Screen for socioeconomic risks during assessments and advocate policy changes for better formulary access.
• Environmental-related factors (e.g., rural-urban access disparities, logistical challenges, social isolation, cultural/religious beliefs, language barriers):
Leverage community-based programs and digital solutions (apps, telehealth, text reminders) to overcome geographical isolation and improve access in underserved areas. Strengthen social support networks via caregiver/family involvement and culturally tailored education. Integrate mental health and social determinant screening, as these often amplify environmental barriers.

​

Imagine a world where patients with heart failure (HF) could fully harness the life-saving potential of their prescribed treatments—reducing hospitalizations by up to 64% and slashing mortality risks. That’s the vision outlined in a pivotal new scientific statement from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the ESC Working Group on Cardiovascular Pharmacotherapy. Published online ahead of print in November 2025 in the European Journal of Heart Failure (DOI: 10.1002/ejhf.70090), this document doesn’t just highlight the problem; it charts a bold path forward, spotlighting tools like the 8-item Morisky Medication Adherence Scale (MMAS-8) as essential allies in the fight.

The Adherence Gap: Why It Matters More Than Ever At its core, the statement underscores adherence as the linchpin of GDMT success. In randomized controlled trials, these therapies shine, cutting cardiovascular mortality and HF hospitalizations by 64% across ejection fraction phenotypes, from reduced (HFrEF) to preserved (HFpEF). But step into routine practice, and the picture dims: Real-world persistence to triple therapy hovers at just 67% in Sweden and plummets to 5% in Norway. For ARNi in HFrEF, achieving a proportion of days covered (PDC) of ≥80% correlates with 31% fewer hospitalizations and 47% lower mortality at one year.
The stakes are personal. Non-adherence erodes quality of life, amplifies multimorbidity burdens, and widens disparities—women, the elderly, and those with low socioeconomic status or depression are hit hardest. Meta-analyses paint a hopeful counterpoint: Interventions boosting adherence can trim death risks by 2–11% and readmissions by 10–21%. As the statement aptly notes, bridging this efficacy-effectiveness gap isn’t optional; it’s imperative for equitable, patient-centered care.
Unpacking the Barriers: A Multidimensional Challenge
This ESC model closely aligns with the World Health Organization’s (WHO) established five dimensions of adherence—patient-related, therapy-related, condition-related, health care system-related, and social/economic factors—but innovatively expands it by adding an environmental dimension to account for logistical and geographical challenges that exacerbate disparities in treatment adherence. By addressing these multifaceted barriers holistically, the framework empowers clinicians to tailor interventions more effectively, ultimately improving outcomes in heart failure management.
Yet, recognition is the first step. By framing adherence as a modifiable determinant—independent of disease severity—the statement empowers clinicians to intervene proactively, much like we’d tackle cholesterol or blood pressure.
​Tools for Success: Enter the MMAS-8
Here’s where the statement truly innovates: It champions practical, scalable tools to measure and mitigate non-adherence, with the MMAS-8 earning a starring role. Listed prominently in Box 1 as a go-to self-report instrument, the MMAS-8 is hailed for its simplicity and low cost in chronic disease settings, including HF. Developed by Donald E. Morisky, this 8-question scale—seven yes/no items plus one 5-point Likert on difficulty remembering—delivers a score from 0 to 8. Higher scores signal better adherence (≥6 generally indicates good compliance), offering quick insights into behavioral patterns and barriers.
Why MMAS-8? It’s not flawless—it can overestimate adherence compared to objective measures like pharmacy refills or electronic monitors—but its utility shines in busy clinics. Validated across languages and populations, including a Vietnamese study of 180 chronic HF patients where it demonstrated strong reliability, the scale integrates seamlessly into routine assessments. As detailed on the official Morisky resource site (moriskyscale.com), MMAS-8 has been battle-tested in cardiovascular contexts, from hypertension to HF, with studies showing its predictive power for outcomes like reduced hospitalizations. In one Portuguese validation for HF outpatients, it correlated tightly with refill data, proving its edge in identifying at-risk patients early.
The statement’s endorsement isn’t casual; it positions MMAS-8 alongside metrics like PDC/MPR and the European Heart Failure Self-care Behaviour Scale (EHFScB-9), urging a hybrid approach. Combine it with simple queries (“Do side effects bother you?”) to uncover why patients skip doses, then tailor fixes—be it education, apps, or polypills that slash pill burdens by 31% in CV settings.

​Read the full statement here: https://doi.org/10.1002/ejhf.70090 License the MMAS-8 for clinical or research use: www.moriskyscale.com
#HeartFailure #Cardiology #MedicationAdherence #MMAS8 #ESCongress #GDMT #WHOAdherence
​

​

The MMAS (Morisky Medication Adherence Scale) and SEAMS (Self-Efficacy for Appropriate Medication Use Scale) are frequently paired in academic research because they complement each other in evaluating medication adherence—a critical factor in managing chronic diseases where non-adherence can lead to poor health outcomes, increased hospitalizations, and higher healthcare costs. Here’s a breakdown of the rationale, drawn from patterns in the literature:
• Complementary Measurement Focus: MMAS is a self-reported tool that directly quantifies adherence behaviors, such as forgetting doses or stopping medication prematurely. It’s simple, validated across cultures (e.g., Chinese or Malaysian versions in several studies), and scores patients as low, medium, or high adherers. SEAMS, on the other hand, measures a patient’s confidence (self-efficacy) in managing medication regimens under various circumstances, like when side effects occur or routines change. Self-efficacy, rooted in Bandura’s social cognitive theory, is a psychological predictor of behavior; low self-efficacy often correlates with poor adherence. Studies use both to capture not just “what” patients do (adherence via MMAS) but “why” they might struggle (self-efficacy via SEAMS), enabling a more holistic analysis.
• Mediation and Correlation Analysis: Many papers explore SEAMS as a mediator or moderator in adherence models. For instance, higher SEAMS scores often predict better MMAS outcomes, as seen in epilepsy or diabetes studies where self-efficacy mediates the impact of depression, health literacy, or temperament on adherence. This allows researchers to test interventions (e.g., education or “talking pill bottles”) that boost self-efficacy to improve adherence. Validation studies also correlate the two for convergent validity, showing strong positive relationships (e.g., r = 0.926 in one Chinese lupus study).
• Application in Specific Populations and Interventions: In pediatric leukemia or rural chronic disease management, both scales help tailor home-based or community interventions. For example, baseline high scores in both might indicate minimal room for improvement in low-literacy groups, while longitudinal tracking shows gains post-intervention. They’re cost-effective, quick to administer, and adaptable to diverse settings like multiple sclerosis or osteoporosis treatment, where adherence to long-term therapies is challenging.
• Broader Research Trends: Adherence research often integrates these with other tools (e.g., beliefs questionnaires or HbA1c tests) to build predictive models. Their joint use stems from the need to address multifaceted barriers—behavioral, psychological, and educational—in real-world clinical practice. As non-adherence affects up to 50% of chronic disease patients globally, combining MMAS (outcome-focused) and SEAMS (process-focused) supports evidence-based strategies for better patient outcomes.

​1. Relationship between Patient Preferences, Attitudes to Treatment, and Adherence to Teriflunomide in Relapsing Multiple Sclerosis (Published in Patient Preference and Adherence, 2022). This study used MMAS-8 to assess adherence to teriflunomide therapy after nine months and SEAMS to evaluate self-efficacy in medication use. 2. Association between Medication Literacy and Medication Adherence among Patients with Hypertension (Published in Frontiers in Public Health, 2023). Researchers applied the Chinese version of MMAS-8 (C-MMAS-8) for adherence measurement and SEAMS for self-efficacy assessment in a cohort of hypertensive patients.
3. Medication Adherence in Leukemia Children Receiving Home-Based Treatment and Its Related Factors (Published in Pediatric Blood & Cancer, 2023). The study incorporated MMAS-8 to gauge adherence levels and SEAMS to measure self-efficacy among pediatric leukemia patients under home care.
4. Management of Chronic Diseases in Rural Areas: A Study of 232 Cases (Published in American Journal of Translational Research, 2022). MMAS-8 and SEAMS were used to score adherence and self-efficacy, respectively, with improvements noted over time in an experimental group receiving interventions.
5. Reliability and Validity of the Chinese Version of the Eight-Item Morisky Medication Adherence Scale in Chinese Patients with Systemic Lupus Erythematosus (Published in International Journal of Rheumatic Diseases, 2022). This validation study correlated MMAS-8 scores with SEAMS to confirm convergent validity.
6. Psychometric Properties of the Osteoporosis-Specific Morisky Medication Adherence Scale in Postmenopausal Women with Osteoporosis Newly Treated with Bisphosphonates (Published in Annals of Pharmacotherapy, 2012). The osteoporosis-specific version of MMAS (OS-MMAS) was evaluated alongside SEAMS and beliefs about medicines questionnaires.
7. Addressing Low Health Literacy with ‘Talking Pill Bottles’: A Pilot Study in a Community Pharmacy Setting (Published in Journal of the American Pharmacists Association, 2017). Both SEAMS and MMAS-8 were employed to track changes in self-efficacy and adherence over 90 days in a low-health-literacy population.
8. Development and Validation of Malaysia Medication Adherence Assessment Tool (MyMAAT) for Diabetic Patients (Published in PLoS One, 2020). MMAS-8 was compared with SEAMS in validating a new adherence tool for diabetes management.
9. The Role of Depressive Symptoms and Self-Efficacy in the Relationship between Temperament and Medication Adherence in Patients with Epilepsy (Published in Epilepsy & Behavior, 2025). MMAS-8 measured adherence, while SEAMS assessed self-efficacy as a mediator in the context of depressive symptoms.
10. Association of Health Literacy and Medication Self-Efficacy with Medication Adherence and Diabetes Control (Published in Patient Preference and Adherence, 2018). SEAMS evaluated self-efficacy, and MMAS assessed adherence in diabetic patients, with links to HbA1c outcomes.
11. The Mediating Effect of Self-Efficacy on the Relationship between Health Literacy and Medication Adherence among Patients with Type 2 Diabetes Mellitus (Published in Patient Preference and Adherence, 2023). SEAMS and MMAS-8 were used to explore mediation effects in diabetes adherence.
12. Depression and Medication Adherence among Older Korean Patients with Hypertension (Published in Asian Nursing Research, 2017). SEAMS and MMAS were part of the assessment battery, with regression analysis on their relationships.
13. The Analysis of Factors Affecting Medication Adherence in Patients with Hypertension (Published in Patient Preference and Adherence, 2024). MMAS-8, SEAMS, and beliefs questionnaires were combined to identify adherence factors.

The Morisky Medication Adherence Scale (MMAS-8) and the Self-Efficacy for Appropriate Medication Use Scale (SEAMS) are both validated self-report tools used to assess medication adherence in chronic diseases, but they serve different purposes. The MMAS-8 is considered a lagging metric because it measures past adherence behaviors and outcomes (e.g., whether patients have already missed doses or deliberately skipped medications), reflecting historical performance. In contrast, the SEAMS is a leading metric because it assesses patients’ confidence (self-efficacy) in managing future medication-taking tasks, predicting potential adherence challenges before they manifest.

As a lagging metric, MMAS-8 is diagnostic, confirming nonadherence after it occurs. It’s useful for assessing the extent of adherence problems and correlating them with clinical outcomes (e.g., poor blood pressure control in hypertension). However, it doesn’t predict future adherence or identify why barriers exist, limiting its proactive utility. For example, a patient scoring low on MMAS-8 (e.g., 4/8) has already exhibited nonadherence, but the tool doesn’t explain underlying confidence or capability issues.

As a leading metric, SEAMS is predictive, identifying patients at risk of nonadherence before it occurs. For example, a patient with low confidence in managing side effects (SEAMS item #11) is likely to skip doses in the future, allowing clinicians to intervene proactively with education or regimen adjustments. Its focus on self-efficacy makes it actionable for tailoring interventions to boost confidence.

Complementary Roles and WHO Barrier Mapping • Lagging vs. Leading Synergy: MMAS-8 and SEAMS complement each other in addressing WHO patient-related barriers:

• MMAS-8 (Lagging): Confirms past nonadherence, quantifying the extent of barriers like forgetfulness (e.g., >50% prevalence in hypertension, AlGhurair et al., 2012) or intentional nonadherence due to low motivation or beliefs. It’s reactive, identifying patients who have already struggled.
​
• SEAMS (Leading): Predicts future nonadherence by assessing confidence deficits that underpin these barriers. For instance, low SEAMS scores on remembering doses (#6) predict forgetfulness, while low scores on managing side effects (#11) predict motivational issues, as seen in myasthenia gravis patients (Wang et al., 2024, OR=1.194 for self-efficacy).

​A Path to Better Adherence
​For researchers and clinicians tackling medication adherence, MMAS-8 and SEAMS are a perfect pair. MMAS-8, the lagging metric, diagnoses past adherence failures, shining a light on barriers like forgetfulness and low motivation. SEAMS, the leading metric, predicts future risks by assessing self-efficacy, empowering proactive solutions. Together, they map WHO patient-related barriers comprehensively, offering actionable insights for your rheumatoid arthritis study in Sudan. By using MMAS-8 to identify nonadherent patients and SEAMS to target confidence deficits, you can design interventions—like education or simplified regimens—that improve outcomes despite economic challenges.

​Let’s leverage these tools to help patients stay on track and reduce flares worldwide! If you’re ready to integrate these into your study, check out the resources or reach out for support.
​


​

​

​

Medication non-adherence is a pervasive challenge in healthcare, contributing to poor health outcomes, increased hospitalizations, and rising costs. The World Health Organization (WHO) identifies five dimensions of barriers to adherence: patient-related, condition-related, therapy-related, health system/healthcare team-related, and social/economic factors. To effectively address non-adherence, clinicians and researchers must first identify whether a patient is non-adherent and whether their non-adherence is intentional (deliberate) or unintentional (e.g., due to forgetfulness). The Morisky Medication Adherence Scale (MMAS-8) is a widely used, validated tool to assess adherence and distinguish between intentional and unintentional non-adherence. By combining MMAS-8 with other validated scales, healthcare providers can pinpoint specific WHO barriers and tailor interventions accordingly. This blog explores how to use the MMAS-8 to assess adherence and leverage complementary scales to identify WHO barriers.
Step 1: Assessing Adherence with the MMAS-8
The MMAS-8 is an 8-item, self-report questionnaire designed to measure medication adherence, particularly for chronic conditions like hypertension, diabetes, or asthma. It is simple to administer, takes about 2–3 minutes, and is validated across diverse populations. The scale includes questions that assess both unintentional and intentional non-adherence, making it an ideal starting point.
How the MMAS-8 Works
• Structure: Seven yes/no questions and one 5-point Likert scale question.
• Scoring: Each item is scored (0 or 1 for yes/no; 0–1 for the Likert scale). Total scores range from 0 to 8:
• High adherence: Score = 8
• Medium adherence: Score = 6 - <8
• Low adherence: Score < 6
• Distinguishing Intentional vs. Unintentional Non-Adherence:
• Unintentional: Items like “Do you sometimes forget to take your pills?” or “Did you not take any of your medicine over the past weekend?” reflect forgetfulness or carelessness.
• Intentional: Items like “Have you ever cut back or stopped taking your medication without telling your doctor because you felt worse?” or “When you feel like it’s not working, do you stop taking it?” indicate deliberate choices.
Using MMAS-8 in Practice
Imagine a patient with type 2 diabetes who scores 4 on the MMAS-8, indicating low adherence. Their responses show they often forget to take their medication (unintentional) but also stop taking it when they feel better (intentional). This dual insight guides the next steps: addressing forgetfulness (e.g., reminders) and exploring reasons for intentional non-adherence (e.g., beliefs or side effects).

​Step 2: Mapping WHO Barriers with Validated Scales Once non-adherence is identified and classified as intentional or unintentional, clinicians can use targeted scales to explore the underlying WHO barriers. Below, we outline each dimension, corresponding scales, and how they complement MMAS-8 findings.
1. Patient-Related Factors
These include knowledge, beliefs, motivation, or psychological factors. Intentional non-adherence often stems from negative beliefs or low motivation, while unintentional non-adherence may relate to cognitive issues.
• Validated Scale: Beliefs about Medicines Questionnaire (BMQ)
• Purpose: Measures beliefs about medication necessity and concerns about side effects.
• How It Helps: If the MMAS-8 indicates intentional non-adherence (e.g., stopping medication due to feeling worse), the BMQ can reveal if this is due to concerns about side effects or low perceived necessity. For example, a patient who believes their diabetes medication is harmful may score high on BMQ-Concerns, guiding interventions like patient education.
• Example: A patient with a high BMQ-Concerns score might benefit from counseling to address misconceptions about medication risks.
• Alternative Scale: Medication Adherence Self-Efficacy Scale (MASES)
• Purpose: Assesses confidence in adhering to medication regimens.
• How It Helps: For unintentional non-adherence (e.g., forgetting doses), low MASES scores may indicate low self-efficacy, suggesting interventions like adherence aids or skill-building.
2. Condition-Related Factors
The nature of the disease (e.g., asymptomatic conditions, chronicity) can affect adherence. For example, patients with asymptomatic hypertension may intentionally skip doses due to a lack of perceived need.
• Validated Scale: Patient Activation Measure (PAM)
• Purpose: Assesses patients’ knowledge, skills, and confidence in managing their condition.
• How It Helps: A low PAM score in a patient with low MMAS-8 adherence may indicate poor understanding of their condition’s severity, contributing to intentional non-adherence. For instance, a hypertensive patient may not see the need for daily medication if they feel fine.
• Example: A low PAM score could prompt disease-specific education to improve condition awareness and adherence.
• Alternative: Disease-specific scales (e.g., Asthma Control Test for asthma) can assess how symptom burden or disease control affects adherence.
3. Therapy-Related Factors
Complex regimens, side effects, or long treatment duration can lead to both intentional (e.g., stopping due to side effects) and unintentional (e.g., missing doses due to complexity) non-adherence.
• Validated Scale: Treatment Satisfaction Questionnaire for Medication (TSQM)
• Purpose: Measures satisfaction with medication, including side effects, convenience, and effectiveness.
• How It Helps: If MMAS-8 shows intentional non-adherence, a low TSQM score for side effects or convenience may explain why. For example, a patient stopping their medication due to gastrointestinal side effects might score low on TSQM-Side Effects.
• Example: Simplifying the regimen or switching medications could address low TSQM scores and improve adherence.
• Alternative: Adherence to Refills and Medications Scale (ARMS) can further explore regimen complexity or refill issues.
4. Health System/Healthcare Team-Related Factors
Poor provider communication, limited access to care, or lack of trust can hinder adherence. These may contribute to intentional non-adherence (e.g., distrust in provider advice) or unintentional (e.g., inability to access refills).
• Validated Scale: Health Care Climate Questionnaire (HCCQ)
• Purpose: Assesses patient perceptions of provider support and communication.
• How It Helps: If MMAS-8 indicates low adherence, a low HCCQ score may suggest poor provider-patient relationships, prompting interventions like shared decision-making or improved communication.
• Example: A patient with a low HCCQ score might benefit from regular follow-ups with a trusted provider to build rapport.
• Alternative: Primary Care Assessment Survey (PCAS) evaluates access and continuity of care, which can uncover system-level barriers.
5. Social and Economic Factors
Cost, social support, health literacy, or cultural beliefs can drive non-adherence. For example, financial barriers may lead to intentional dose-skipping, while low social support may cause unintentional lapses.
• Validated Scale: Social Support Survey (SSS)
• Purpose: Measures perceived social support for health behaviors.
• How It Helps: A patient with unintentional non-adherence on MMAS-8 and low SSS scores may lack support for medication routines, suggesting interventions like involving family or community resources.
• Example: Connecting a patient with a support group could improve adherence if SSS scores are low.
• Alternative: Medication Access and Adherence Tool (MAAT) assesses cost-related barriers, particularly in low-resource settings.

​Step 3: Integrating Findings for Tailored Interventions with the MAAP In the blog’s Step 3, we discussed integrating findings from the Morisky Medication Adherence Scale (MMAS-8) with validated scales to map barriers to medication adherence across the five WHO dimensions and design tailored interventions. Here, we expand on this by incorporating the Medication Adherence Assessment Protocol (MAAP), a structured approach that can complement the MMAS-8 and other scales to systematically address adherence barriers, particularly for the social and economic dimension, but also applicable across all dimensions. The MAAP, while not as commonly referenced as scales like the BMQ or TSQM, is a framework used in some clinical and research settings to assess and address adherence barriers comprehensively. Below, we discuss how the MAAP can be integrated into Step 3 to enhance the intervention process.
What is the MAAP?
The Medication Adherence Assessment Protocol (MAAP) is a structured, multi-step process designed to assess medication adherence, identify barriers, and guide interventions. It typically involves:
• Assessment: Using standardized tools (like MMAS-8) to measure adherence and classify it as intentional or unintentional.
• Barrier Identification: Pinpointing specific barriers across the WHO dimensions through patient interviews, questionnaires, or validated scales.
• Intervention Planning: Developing tailored strategies based on identified barriers, often involving interdisciplinary collaboration.
• Follow-Up: Monitoring adherence over time to evaluate intervention effectiveness.
The MAAP is flexible and can incorporate various validated scales, making it ideal for integrating MMAS-8 findings with tools like the Beliefs about Medicines Questionnaire (BMQ), Patient Activation Measure (PAM), Treatment Satisfaction Questionnaire for Medication (TSQM), Health Care Climate Questionnaire (HCCQ), and Social Support Survey (SSS). It emphasizes patient-centered care and iterative refinement of interventions.

Step 1: Check for Peer-Reviewed Validation Studies
The first indicator of a validated assessment is the presence of peer-reviewed studies confirming its reliability and validity. Look for published research in reputable journals (e.g., PubMed, JAMA) that detail the assessment’s development and testing.

Step 2: Evaluate Reliability Metrics
A validated assessment should provide quantifiable evidence of consistency. Check for metrics such as internal consistency (e.g., Cronbach’s alpha ≥ 0.7) or test-retest reliability, which measure how reliably the tool produces the same results under consistent conditions.

Step 3: Assess Construct and Convergent Validity
Validation requires proof that the assessment measures what it intends to and aligns with established tools. Look for evidence of construct validity (does it measure adherence effectively?) and convergent validity (does it correlate with other validated measures?).

Step 4: Review Population Diversity in Testing
A truly validated assessment should be tested across diverse demographics, including age, gender, ethnicity, and geographic regions. This ensures generalizability.

Step 5: Seek Independent Replication
Validation is strengthened when independent studies replicate the original findings. Search for research from multiple sources confirming the assessment’s effectiveness.

Why It Matters
Using unvalidated assessments can lead to AI models that misclassify patient data—such as overestimating medication adherence, as seen in a 2022 case where an AI tool for opioid prescriptions contributed to overdoses due to flawed data. Validated tools mitigate these risks, ensuring AI enhances healthcare analytics, telehealth, and personalized medicine safely.

The Morisky Medication Adherence Scale (MMAS) has become a cornerstone in healthcare for assessing patient adherence to prescribed medication regimens. Renowned for its reliability, validity, and global applicability, the MMAS is not only synonymous with medication adherence but also an ideal tool for training AI learning models to enhance patient outcomes. This blog explores why the Morisky Scale is a gold standard in adherence science and how its structured, behavior-focused design makes it perfect for AI model training in healthcare.
The Morisky Scale: A Gold Standard in Medication Adherence
Developed by Dr. Donald E. Morisky, the MMAS began as a four-item questionnaire (MMAS-4) in 1986, designed to evaluate adherence to antihypertensive medications. It evolved into the more comprehensive MMAS-8, an eight-item scale that captures nuanced reasons for non-adherence across diverse patient populations and conditions, including diabetes, hypertension, HIV, and cancer. With over 32,000 citations and validation in over 90 countries, the MMAS is trusted by major pharmaceutical companies like Novartis and Pfizer, as well as healthcare providers worldwide.
The MMAS stands out due to its:
• Simplicity: Its concise, structured questions (seven yes/no and one Likert-scale question) make it easy to administer in clinical and research settings.
• Behavioral Focus: The scale identifies specific reasons for non-adherence, such as forgetting doses, stopping medication when feeling better, or skipping doses due to side effects.
• Global Validation: Independently validated across various diseases, languages, and cultures, the MMAS ensures consistent and reliable results.
• Actionable Insights: It categorizes adherence as low, medium, or high, enabling healthcare providers to create targeted interventions.
These qualities make the MMAS the go-to tool for measuring medication adherence, a critical factor in managing chronic diseases and improving health outcomes.
Why the Morisky Scale is Ideal for Training AI Learning Models
The integration of artificial intelligence (AI) in healthcare is transforming how we address challenges like medication non-adherence, which affects up to 50% of patients with chronic conditions. The MMAS’s structured design and robust validation make it an exceptional dataset for training AI learning models. Here’s why:
1. Structured and Quantifiable Data
The MMAS provides clear, quantifiable outputs (adherence scores) based on patient responses to its eight questions. This structured format is ideal for machine learning models, which thrive on consistent, well-organized data. For example, the MMAS-8 score (ranging from 0 to 8) can be used to train AI algorithms to predict adherence levels and identify at-risk patients. The binary (yes/no) and ordinal (Likert-scale) responses are easily encoded for AI processing, enabling models to analyze patterns in adherence behavior.
2. Behavioral Insights for Predictive Modeling
The MMAS captures specific reasons for non-adherence, such as forgetfulness or intentional discontinuation due to side effects. These behavioral insights allow AI models to go beyond simple predictions and identify underlying causes of non-adherence. For instance, an AI model trained on MMAS data could predict that a patient who frequently forgets doses might benefit from reminders via a health app or telehealth solution. This makes the MMAS a powerful tool for developing personalized medicine interventions.
3. Extensive Validation for Robust AI Training
The MMAS’s global validation across diverse conditions (e.g., type 2 diabetes, osteoporosis, chronic pain) and populations ensures that AI models trained on its data are generalizable. A 2017 systematic review found that the MMAS-8 has acceptable internal consistency (Cronbach’s α of 0.67 for diabetes and 0.77 for osteoporosis) and good convergent validity with other adherence measures. This reliability minimizes bias in AI training datasets, ensuring models produce accurate and trustworthy predictions.
4. Scalability for Large-Scale AI Applications
With its use in over 90 countries and translations into 80 languages, the MMAS provides a scalable dataset for training AI models across global healthcare systems. This is particularly valuable for health tech startups and healthcare analytics companies developing AI-driven tools for population health management. The MMAS’s widespread adoption ensures that AI models can be applied to diverse patient demographics, from rural clinics in Bhutan to urban hospitals in the U.S.
5. Integration with Digital Health Technologies
The MMAS aligns seamlessly with digital health tools like remote patient monitoring, mhealth, and telemedicine. AI models trained on MMAS data can be integrated into these platforms to provide real-time adherence monitoring and personalized interventions. For example, a wearable health device could use an AI model to analyze MMAS responses and send tailored reminders to patients, improving adherence rates. The MMAS’s compatibility with health informatics makes it a critical asset for AI-driven virtual care.
6. Support for Ethical AI Development
Training AI models requires adherence to ethical standards, including data fidelity and proper licensing. The MMAS is a proprietary tool, and its use is governed by strict licensing agreements through MMAR, LLC. This ensures that AI models trained on MMAS data maintain fidelity to the original validated structure, reducing the risk of misinterpretation or misuse. The mandatory Ξxpert training for MMAS users further ensures that AI developers understand the scale’s nuances, enhancing the ethical deployment of AI in healthcare.